Author response-Rituximab versus ocrelizumab: When inference exceeds the evidence. Chu NY, Roberts JI, Schabas AJ Mult Scler. 2026 Oct 18:13524585261496131. PMID: 42894329. Abstract CommentRecommendBookmarkWatch
